Table 7.
Risk of cardiovascular diseases in the two drug groups after matching between 2016 and 2018 (without cardiovascular disease history)
| Classification | Febuxostat (21,402 patients) | Allopurinol (21,402 patients) | HR (95% CI) | ||||
|---|---|---|---|---|---|---|---|
| Number of patients (n) | Person–years | Incidence rate (1000 person –years) | Number of patients (n) | Person–years | Incidence rate (1000 person –years) | ||
| Primary outcome variable* | |||||||
| Cardiovascular disease | 362 | 17,737.3 | 20.4 | 386 | 20,984.8 | 18.4 | 1.11 (0.96–1.28) |
| Secondary outcome variable | |||||||
| Myocardial infarction | 33 | 17,952.1 | 1.8 | 31 | 21,226.4 | 1.5 | 1.28 (0.78–2.09) |
| Ischemic heart disease | 102 | 17,913.8 | 5.7 | 105 | 21,180.4 | 5.0 | 1.15 (0.87–1.50) |
| Stroke | 90 | 17,913.7 | 5.0 | 114 | 21,168.2 | 5.4 | 0.93 (0.70–1.22) |
| Transient ischemic attack | 41 | 17,939.0 | 2.3 | 38 | 21,218.1 | 1.8 | 1.28 (0.82–2.00) |
| Heart failure | 170 | 17,854.6 | 9.5 | 165 | 21,140.3 | 7.8 | 1.22 (0.98–1.51) |
| Coronary revascularization (treatment) | 18 | 17,959.0 | 1.0 | 16 | 21,236.4 | 0.8 | 1.46 (0.70–3.05) |
| All-cause death | 2 | 17,737.3 | 0.1 | 3 | 20,984.8 | 0.1 | 0.87 (0.14–5.24) |
*All-cause death: includes 2 and 3 patients in the febuxostat and allopurinol groups, respectively
Coronary revascularization is a treatment code that has secondary outcome variables and overlapping values